An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ocuphire Pharma, Inc. announces that Dr. Daniel Su will present a paper on oral APX3330 at the ARVO 2024 Annual Meeting. The meeting will take place from May 5-9, 2024, in Seattle, Washington.
Ocuphire Pharma, Inc. annuncia che il Dr. Daniel Su presenterà un documento sull'APX3330 orale al Congresso Annuale ARVO 2024. Il congresso si terrà dal 5 al 9 maggio 2024, a Seattle, Washington.
Ocuphire Pharma, Inc. anuncia que el Dr. Daniel Su presentará un informe sobre el APX3330 oral en la Reunión Anual de ARVO 2024. El evento se llevará a cabo del 5 al 9 de mayo de 2024, en Seattle, Washington.
Ocuphire Pharma, Inc.는 다니엘 수 박사가 2024년 ARVO 연례 회의에서 구두 APX3330에 대한 논문을 발표할 것이라고 발표했습니다. 이 회의는 2024년 5월 5일부터 9일까지 워싱턴주 시애틀에서 개최됩니다.
Ocuphire Pharma, Inc. annonce que le Dr Daniel Su présentera un document sur l'APX3330 oral lors de la Réunion Annuelle de l'ARVO 2024. La réunion aura lieu du 5 au 9 mai 2024, à Seattle, Washington.
Ocuphire Pharma, Inc. gibt bekannt, dass Dr. Daniel Su auf der ARVO-Jahrestagung 2024 einen Bericht über das orale APX3330 vorstellen wird. Die Tagung findet vom 5. bis 9. Mai 2024 in Seattle, Washington, statt.
Positive
None.
Negative
None.
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington.
Key details about Dr. Su’s presentation at the ARVO 2024 Annual Meeting are below:
Title of Presentation:
Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale
Presenter:
Daniel Su, M.D., Retina Vitreous Associates Medical Group
Presentation Number:
658
Paper Session:
Diabetic Retinopathy
Date:
Sunday, May 5, 2024
Time:
4:00 – 4:15 pm PT
Location:
Arch Building, 6E, Seattle Convention Center
About Ocuphire Pharma
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders.
Ocuphire’s lead retinal product candidate, APX3330, is an oral small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) for the treatment of non-proliferative diabetic retinopathy (NPDR). Ref-1 is a regulator of the transcription factors HIF-1α and NF-κB. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of diabetic retinopathy (DR). A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have been completed, and a special protocol assessment (SPA) was submitted to the U.S. Food and Drug Administration (FDA) in February 2024.
In addition, Ocuphire has a partnership with Viatris to develop and commercialize Phentolamine Ophthalmic Solution 0.75% (“PS”), a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. PS was approved by the FDA for the treatment for pharmacologically-induced mydriasis under the brand name RYZUMVI™ in September 2023. PS is also in Phase 3 clinical development for the treatment of presbyopia and for the treatment of decreased visual acuity under low light (mesopic) conditions after keratorefractive surgery.
Ocuphire is also developing APX2009 and APX2014, second-generation analogs of APX3330. These programs are being evaluated for treating other retinal diseases such as age-related macular degeneration and geographic atrophy. For more information, please visit www.ocuphire.com.
ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.